Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | CASP3 | P42574 | 2/20 | 0.71 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.71 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.71 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PLEC | Q15149 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297148 | 1.00 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL189965 | 1.00 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL12271842 | 0.83 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL15776771 | 0.83 | NPC1 (0.77) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL12271844 | 0.83 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL15776773 | 0.83 | NPC1 (0.77) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL17625509 | 0.83 | MEN1 (0.66) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL10890571 | 0.82 | MAOB (0.65) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6263881 | 0.82 | MAOB (0.65) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9819902 | 0.82 | KMT2A (0.59) | RAB9ANPC1SMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861069-B | Preparation method of nitrile compound | 陕西国际商贸学院 | 2023-06-16 | — | — | CN | disclosed |
| CN-113861069-A | Preparation method of nitrile compound | 陕西国际商贸学院 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021014395-A1 | PROCESS FOR THE SYNTHESIS OF DEUTERATED CAPSAICIN, CAPSAICINOIDS AND SYNTHETIC CAPSAICIN ANALOGS | DR. REDDY’S INSTITUTE OF LIFE SCIENCES (IN) | 2021-01-28 | — | — | WO | disclosed |
| US-9290464-B2 | Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-03-22 | — | — | US | disclosed |
| EP-2401263-B1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-02-17 | — | — | EP | disclosed |
| EP-2308838-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2016-02-17 | — | — | EP | disclosed |
| US-9150563-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140350062-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION | SK BIOPHARMACEUTICALS CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-8841335-B2 | Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-23 | — | — | US | disclosed |
| US-8828992-B2 | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-09 | — | — | US | disclosed |
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2011-12-08 | — | — | US | disclosed |
| WO-2011139079-A2 | PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-11-10 | — | — | WO | disclosed |
| EP-2308838-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010098600-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK HOLDINGS CO., LTD. (KR) | 2010-09-02 | — | — | WO | disclosed |
| EP-0196184-B1 | ARYL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-16 | — | — | EP | disclosed |
| US-5036157-A | Hydroxamic acid derivatives, lipoxygenase and cyclooxygenase inhibitors, anticoagulants, antiinflammatory agents | BURROUGHS WELLCOME CO. | 1991-07-30 | — | — | US | disclosed |
| US-4977188-A | Hydroamic acid derivatives | BURROUGHS WELLCOME CO. (US) | 1990-12-11 | — | — | US | disclosed |
| WO-1990001929-A1 | NEW MEDICAL USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-03-08 | — | — | WO | disclosed |
| US-4738986-A | CYCLOOXYGENASE, LIDOXYGENASE INHIBITORS | BURROUGHS WELLCOME CO. (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0196184-A2 | Aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | MAOB, MAOA, PARK7 | RAB9A 1245/4885NPC1 1852/4885SMN1; SMN2 268/4885 |
| US-20140350062-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION | BAX, NLN, CASP3 | RAB9A 2788/4885NPC1 134/4885SMN1; SMN2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.